Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8160823 | 0.82 | KDM5A (0.46) | EPHX2KDM5AVNN1F10NPC1 | |
| SCHEMBL4516164 | 0.82 | L3MBTL1 (0.52) | ALDH1A1 | |
| SCHEMBL15264280 | 0.80 | KDM5A (0.44) | KDM5AVNN1F10NPC1RAB9A | |
| SCHEMBL19001333 | 0.79 | KDM5A (0.50) | KDM5AVNN1F10ALDH1A1NPC1 | |
| SCHEMBL15998852 | 0.79 | KDM5A (0.40) | EPHX2KDM5AVNN1KDM6BKDM5C | |
| SCHEMBL10074929 | 0.79 | KDM5A (0.43) | KDM5AVNN1F10NPC1RAB9A | |
| SCHEMBL18701762 | 0.78 | VNN1 (0.46) | KDM5AVNN1F10NPC1RAB9A | |
| SCHEMBL10074405 | 0.78 | NPC1 (0.44) | KDM5AVNN1F10NPC1RAB9A | |
| SCHEMBL10074641 | 0.78 | POLB (0.46) | KDM5AVNN1F10ALDH1A1NPC1 | |
| SCHEMBL12842023 | 0.77 | OPRL1 (0.41) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | EPHX2 2625/4885KDM5A 3421/4885VNN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.